Casgevy (exagamglogene autotemcel, or exa-cel) is a one-time gene-editing therapy for sickle cell disease. It uses CRISPR technology to edit a patient’s own blood stem cells so they produce high levels of fetal hemoglobin, a form of hemoglobin that does not sickle. In the US it is approved for people aged 12 and older with sickle cell disease who have recurrent vaso-occlusive (pain) crises, and it was the first CRISPR-based medicine to reach patients.
Casgevy sickle cell treatment is a major step forward, but it is also an intensive process. This overview explains how it works, who may qualify, what treatment involves, and the risks to weigh.
Sickle Cell Disease: The Problem Casgevy Targets
Sickle cell disease (SCD) is an inherited disorder caused by a single change in the HBB gene, which makes the beta-globin part of hemoglobin. The altered protein is called hemoglobin S. When oxygen levels fall, hemoglobin S molecules stick together into rigid fibers, bending red cells into a crescent or “sickle” shape.
A person who inherits one sickle gene and one normal gene has sickle cell trait and is usually healthy. Two sickle genes, or one sickle gene plus another hemoglobin variant such as beta-thalassemia, cause disease. The biology of sickle hemoglobin explains nearly every complication patients face.
Why sickled cells cause harm
Healthy red blood cells are flexible discs that live about 120 days. Sickled cells are stiff, block small blood vessels, and break down within a few weeks. This produces:
- Sudden, severe pain episodes called vaso-occlusive crises
- Chronic anemia and fatigue
- Acute chest syndrome, stroke, and damage to the spleen, kidneys, and other organs
- Higher risk of serious infections
These complications shape the life span of people with sickle cell disease, which is why curative options matter so much.
How Casgevy Works
Casgevy does not repair the sickle mutation itself. Instead, it switches back on a gene that is normally silenced after birth. Before birth, babies make fetal hemoglobin (HbF). After birth, a protein called BCL11A turns HbF production down, and adult hemoglobin takes over.
Doctors have long observed that people with sickle cell disease who naturally keep high HbF levels have milder disease. Fetal hemoglobin dilutes hemoglobin S inside each red cell and stops it from forming fibers.
Casgevy uses CRISPR-Cas9, a molecular “scissors” tool, to cut a specific control region (an enhancer) of the BCL11A gene in blood-forming stem cells. With that enhancer disrupted, BCL11A is reduced only in red-cell precursors, and those cells go back to producing large amounts of fetal hemoglobin for life.
What Treatment Involves, Step by Step
Casgevy is made from each patient’s own cells, so it is an autologous therapy with no need for a matched donor. The process takes many months from start to finish.
| Stage | What happens |
|---|---|
| 1. Evaluation | Assessment at a specialist center; fertility counseling and preservation discussed |
| 2. Preparation | Regular red cell transfusions for several weeks to lower hemoglobin S |
| 3. Stem cell collection | A mobilizing drug (plerixafor) releases stem cells from the bone marrow into the blood, where they are collected by apheresis; more than one cycle may be needed |
| 4. Manufacturing | Cells are edited in a laboratory and quality-tested, which takes months |
| 5. Conditioning | High-dose busulfan chemotherapy clears the existing marrow to make room for edited cells |
| 6. Infusion | Edited cells are given back through a vein as a single infusion |
| 7. Recovery | Several weeks in hospital until blood counts recover (engraftment), then long-term follow-up |
Benefits, Risks, and Who Qualifies
In clinical trials, most treated patients stopped having severe vaso-occlusive crises during follow-up, and fetal hemoglobin rose to levels associated with very mild disease. Hospital admissions and transfusion needs fell substantially. Long-term data are still being gathered, so patients are followed for many years.
Main risks
Most of the risk comes from the busulfan conditioning rather than the edited cells:
- Very low blood counts for weeks, with risk of serious infection and bleeding
- Mouth sores, nausea, and hair loss
- Infertility, which may be permanent, so egg or sperm preservation is offered beforehand
- A possible long-term risk of blood cancers linked to chemotherapy
- Unknown long-term effects of gene editing, which is why follow-up continues for years
Who may be a candidate
Candidates are generally aged 12 or older, have recurrent pain crises despite standard care, and are well enough to tolerate myeloablative chemotherapy. Cost and access to an authorized treatment center are real barriers in many countries.
How Casgevy Compares with Other Treatments
| Treatment | Goal | Key considerations |
|---|---|---|
| Hydroxyurea | Raises fetal hemoglobin, reduces crises | Daily oral drug; widely available; ongoing monitoring |
| Regular transfusions | Lowers hemoglobin S; stroke prevention | Iron overload; need for chelation |
| Donor stem cell transplant | Potential cure | Needs a matched donor; risk of graft-versus-host disease |
| Lyfgenia (gene addition) | Adds a modified anti-sickling globin gene | Also uses own cells and busulfan; boxed warning for blood cancer |
| Casgevy (gene editing) | Reactivates fetal hemoglobin | Own cells, no donor needed; busulfan conditioning; very high cost |
Casgevy is also approved for transfusion-dependent beta-thalassemia, another of the genetic blood disorders that respond to higher fetal hemoglobin. For a broader look at care options, see our sickle cell guide.
Key Takeaways
- Casgevy is a one-time CRISPR gene-editing therapy that makes red cells produce fetal hemoglobin, preventing sickling.
- It uses the patient’s own stem cells, so no donor is needed.
- Treatment requires stem cell collection, months of manufacturing, and high-dose chemotherapy before infusion.
- Most risk comes from chemotherapy conditioning, including infertility and infection.
- It is a significant advance in hematology, and decisions should be made with a specialist team experienced in hematological disorders.
Frequently Asked Questions
Is Casgevy a cure for sickle cell disease?
Casgevy is described as potentially curative because a single treatment can eliminate crises for years. The underlying sickle mutation remains, however, and long-term durability is still being studied. Patients still carry the sickle gene and can pass it to their children.
How is Casgevy different from a bone marrow transplant?
A traditional transplant uses stem cells from a matched donor, which brings the risk of rejection and graft-versus-host disease. Casgevy uses the patient’s own edited cells, so those immune risks are avoided. Both still require chemotherapy conditioning.
How long is the hospital stay for Casgevy?
The infusion itself is quick, but patients typically stay in hospital for several weeks after conditioning until their blood counts recover. The full journey, from evaluation to recovery, usually spans many months.
Will I still need hydroxyurea after Casgevy?
Hydroxyurea is stopped some weeks before stem cell collection, and it is generally not needed afterward if fetal hemoglobin rises as expected. Transfusions are also usually no longer required once counts recover. Your specialist team decides based on your blood results, and long-term follow-up continues.
